Tianyu Co., Ltd. announced that Zhejiang Nuode Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for vonoracin fumarate tablets approved and issued by the State Drug Administration. The registration classification is 4 types of chemicals, with specifications of 10 mg and 20 mg. The indications are reflux esophagitis, used in combination with appropriate antibiotics to eradicate Helicobacter pylori. The approval number is valid until October 19, 2031. As of September 30, 2026, the company and its subsidiaries have invested a total of about 5.7517 million yuan in R&D of this variety. The drug has been approved to be manufactured and sold domestically, enriching the company's formulation variety, and is expected to increase revenue from the formulation business, but there is uncertainty about its future profit level.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.